
PTC Therapeutics fell 21.3% from $76.69 to $60.36, behind the S&P 500's +10.6%. Its worst day was Dec 3 (−11.9%), and its low came Oct 16 at $59.24.
Nov 18, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
PTC Therapeutics shares fell 11.9%, while the S&P 500 rose 0.1%.
−11.9%, the year's worst day · S&P 500 +0.1%
EPS of $-1.67 missed the $-0.33 estimate on $164.7M revenue (est. $295.4M); FY revenue guidance of $700.0M–$800.0M against the $974.0M consensus.
Story events cover the past 12 months · Times ET
+1.1% · S&P 500 +0.7%
PTC Therapeutics shares rose 8.9%, while the S&P 500 rose 0.9%.
+8.9% · S&P 500 +0.9%
- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose -- Continued evidence of favorable safety profile - - Novartis initiated global
−8.1% · S&P 500 0.0%
EPS of $-0.03 beat the $-0.41 estimate on $272.6M revenue (est. $227.5M); FY revenue guidance of $1.1B–$1.2B against the $1.0B consensus.
+14.3%, the year's best day · S&P 500 +0.8%
PTC Therapeutics shares fell 7.5%, while the S&P 500 rose 0.1%.
−7.5% · S&P 500 +0.1%
PTC Therapeutics closed at its highest level of the year, 16.8% above where the year started.
+1.1% · S&P 500 +0.8%
EPS of $0.92 beat the $0.31 estimate on $360.5M revenue (est. $292.7M); FY revenue guidance of $1.2B–$1.3B against the $1.2B consensus.
−9.9% · S&P 500 +0.7%
PTC Therapeutics closed at its lowest level of the year, 22.8% below where the year started.
−2.9% · S&P 500 −1.1%
EPS of $0.94 beat the $0.27 estimate on $357.8M revenue (est. $306.2M); FY revenue guidance of $1.3B–$1.3B against the $1.3B consensus.
−7.0% · S&P 500 −1.8%
Where it ended: a close of $60.36 on Nov 17, 2026. Up next: Q4 2026 earnings on Feb 18, 2027 (EPS est. $0.20, revenue est. $330.2M).
Nothing in the past 12 months.
All PTCT dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PTCT and SPY from Benzinga historical bars. Not investment advice.